<DOC>
	<DOCNO>NCT01343966</DOCNO>
	<brief_summary>This Phase II , randomize , double-blind , parallel-group , placebo-controlled study evaluate safety efficacy MABT5102A patient mild moderate Alzheimer 's Disease .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety MABT5102A Patients With Mild Moderate Alzheimer 's Disease ( ABBY )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis probable AD accord National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorder Association ( NINCDSADRDA ) criteria MiniMental State Examination ( MMSE ) score 1826 point screen Geriatric Depression Scale ( GDS15 ) score &lt; 6 Completion 6 year education ( good work history consistent exclusion mental retardation pervasive developmental disorder ) If receive concurrent AD treatment , patient must medication least 3 month stable dose least 2 month prior randomization . Severe unstable medical condition , opinion investigator Sponsor , would interfere patient 's ability complete study assessment would require equivalent institutional hospital care History presence clinically evident vascular disease potentially affect brain History severe , clinically significant ( persistent neurologic deficit structural brain damage ) central nervous system trauma Hospitalization within 4 week prior screen Previous treatment MABT5102A therapeutic target Abeta Treatment biologic therapy within 5 halflives 3 month prior screen , whichever longer , exception routinely recommend vaccination , allow</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>